ERDRP-0519 inhibits feline coronavirus in vitro.
Antiviral
Cat
ERDRP-0519
Feline coronavirus (FCoV)
Feline infectious peritonitis (FIP)
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
25 Jan 2022
25 Jan 2022
Historique:
received:
01
12
2020
accepted:
07
01
2022
entrez:
26
1
2022
pubmed:
27
1
2022
medline:
4
2
2022
Statut:
epublish
Résumé
Coronaviruses (CoVs) are major human and animal pathogens and antiviral drugs are pursued as a complementary strategy, chiefly if vaccines are not available. Feline infectious peritonitis (FIP) is a fatal systemic disease of felids caused by FIP virus (FIPV), a virulent pathotype of feline enteric coronavirus (FeCoV). Some antiviral drugs active on FIPV have been identified, but they are not available in veterinary medicine. ERDRP-0519 (ERDRP) is a non-nucleoside inhibitor, targeting viral RNA polymerase, effective against morbilliviruses in vitro and in vivo. The antiviral efficacy of ERDRP against a type II FIPV was evaluated in vitro in Crandell Reese Feline Kidney (CRFK) cells. ERDRP significantly inhibited replication of FIPV in a dose-dependent manner. Viral infectivity was decreased by up to 3.00 logarithms in cell cultures whilst viral load, estimated by quantification of nucleic acids, was reduced by nearly 3.11 logaritms. These findings confirm that ERDRP is highly effective against a CoV. Experiments will be necessary to assess whether ERDRP is suitable for treatment of FIPV in vivo.
Sections du résumé
BACKGROUND
BACKGROUND
Coronaviruses (CoVs) are major human and animal pathogens and antiviral drugs are pursued as a complementary strategy, chiefly if vaccines are not available. Feline infectious peritonitis (FIP) is a fatal systemic disease of felids caused by FIP virus (FIPV), a virulent pathotype of feline enteric coronavirus (FeCoV). Some antiviral drugs active on FIPV have been identified, but they are not available in veterinary medicine. ERDRP-0519 (ERDRP) is a non-nucleoside inhibitor, targeting viral RNA polymerase, effective against morbilliviruses in vitro and in vivo.
RESULTS
RESULTS
The antiviral efficacy of ERDRP against a type II FIPV was evaluated in vitro in Crandell Reese Feline Kidney (CRFK) cells. ERDRP significantly inhibited replication of FIPV in a dose-dependent manner. Viral infectivity was decreased by up to 3.00 logarithms in cell cultures whilst viral load, estimated by quantification of nucleic acids, was reduced by nearly 3.11 logaritms.
CONCLUSIONS
CONCLUSIONS
These findings confirm that ERDRP is highly effective against a CoV. Experiments will be necessary to assess whether ERDRP is suitable for treatment of FIPV in vivo.
Identifiants
pubmed: 35078478
doi: 10.1186/s12917-022-03153-3
pii: 10.1186/s12917-022-03153-3
pmc: PMC8787031
doi:
Substances chimiques
Antiviral Agents
0
ERDRP-0519
0
Morpholines
0
Piperidines
0
Pyrazoles
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
55Informations de copyright
© 2022. The Author(s).
Références
J Feline Med Surg. 2013 Sep;15(9):785-808
pubmed: 23966005
J Gen Virol. 2003 Oct;84(Pt 10):2735-2744
pubmed: 13679608
Mol Biol. 2020 Sep 4;:1-15
pubmed: 32921819
J Feline Med Surg. 2004 Apr;6(2):59-62
pubmed: 15123149
Sci Transl Med. 2014 Apr 16;6(232):232ra52
pubmed: 24739760
J Virol Methods. 1999 Jan;77(1):37-46
pubmed: 10029323
Cell Mol Life Sci. 2014 Nov;71(22):4403-20
pubmed: 25080879
Vaccine. 2020 Jul 14;38(33):5123-5130
pubmed: 32563608
EMBO J. 1989 Dec 1;8(12):3867-74
pubmed: 2555175
Vet Clin North Am Small Anim Pract. 2011 Nov;41(6):1133-69
pubmed: 22041208
Int J Mol Sci. 2015 Jun 08;16(6):12943-57
pubmed: 26062131
J Feline Med Surg. 2019 Apr;21(4):271-281
pubmed: 30755068
PLoS Pathog. 2013;9(8):e1003549
pubmed: 23950717
Vet Microbiol. 2018 Jun;219:226-233
pubmed: 29778200
Res Vet Sci. 2019 Aug;125:421-424
pubmed: 29113645
Clin Diagn Lab Immunol. 2005 Oct;12(10):1209-15
pubmed: 16210485
J Virol. 1998 May;72(5):4508-14
pubmed: 9557750
PLoS Pathog. 2021 Feb 23;17(2):e1009371
pubmed: 33621266
Nature. 2014 Dec 18;516(7531):355-60
pubmed: 25409142
Nature. 2020 Aug;584(7819):154-156
pubmed: 32438371
Viruses. 2020 May 24;12(5):
pubmed: 32456286
J Feline Med Surg. 2018 Apr;20(4):378-392
pubmed: 28901812
mBio. 2018 Nov 27;9(6):
pubmed: 30482837
J Mol Biol. 2002 Nov 15;324(1):47-62
pubmed: 12421558
Med Chem Res. 2020 Sep 10;:1-21
pubmed: 32929317
Phytomedicine. 2021 Jun;86:153440
pubmed: 33376043
J Vet Intern Med. 2007 Nov-Dec;21(6):1193-7
pubmed: 18196725
Vet J. 2014 Aug;201(2):123-32
pubmed: 24837550
J Biol Chem. 2004 Nov 5;279(45):47212-21
pubmed: 15294895
Adv Virus Res. 2016;96:193-218
pubmed: 27712624
Antiviral Res. 2013 Aug;99(2):100-7
pubmed: 23648708
Ann Transl Med. 2015 May;3(Suppl 1):S15
pubmed: 26046060
Acta Pharm Sin B. 2021 Jun;11(6):1555-1567
pubmed: 33614402
One Health. 2020 Mar 27;9:100128
pubmed: 32258351
J Immunol Methods. 1986 May 22;89(2):271-7
pubmed: 3486233
EMBO J. 2004 Sep 1;23(17):3462-71
pubmed: 15306852
J Feline Med Surg. 2009 Jul;11(7):594-604
pubmed: 19481039
Cell. 2015 Jul 16;162(2):314-327
pubmed: 26144317
Res Vet Sci. 2019 Oct;126:113-117
pubmed: 31445397
Nucleic Acids Res. 2003 Apr 1;31(7):1821-9
pubmed: 12654997
J Virol. 1992 Feb;66(2):956-65
pubmed: 1309922
Front Microbiol. 2019 Jul 10;10:1490
pubmed: 31354644
Methods Mol Biol. 2015;1282:1-23
pubmed: 25720466